Common Contracts

6 similar null contracts by Duramed Pharmaceuticals Inc, JLG Industries Inc, Marlin Capital Lp, others

EXHIBIT 10.5 INCREMENTAL TERM LOAN COMMITMENT AGREEMENT
Vanguard Health Systems Inc • January 14th, 2003 • Hospital & medical service plans • New York
AutoNDA by SimpleDocs
CONSENT
Switchboard Inc • May 9th, 2002 • Services-business services, nec

Subject to the sale by Switchboard Incorporated, a Delaware corporation (the "Corporation"), to the undersigned of 450,000 shares of common stock, $.01 par value per share, of the Corporation (the "Common Stock") pursuant to and in accordance with the terms of that certain Restricted Stock Agreement of even date herewith between the Corporation and the undersigned, the undersigned hereby consents to the termination and cancellation by the Corporation of options to purchase 900,000 shares of Common Stock granted to the undersigned by the Corporation on October 13, 1999.

As of January 29, 2000 VIA FACSIMILE (512) 478-5733 ------------- Mr. Thomas Cooke 301 Congress Avenue Suite 1550 Austin, TX 78701 Dear Mr. Cooke: As you know, PrimeVision Health, Inc. (the "Company") and you are parties to a voting agreement (the...
Marlin Capital Lp • February 10th, 2000 • Services-offices & clinics of doctors of medicine

As you know, PrimeVision Health, Inc. (the "Company") and you are parties to a voting agreement (the "Agreement") pursuant to which you granted, for the benefit of the Company, to the Company's representatives a proxy to vote what are now shares of OptiCare Eye Health Systems, Inc. on all matters to be submitted to the shareholders of OptiCare Health Systems.

Exhibit 11(b)(2) [Borden, Inc. Letterhead] October 1, 1997 Mr. James O. Stevning Chief Financial Officer Borden Chemical, Inc. 180 East Broad Street Columbus, OH 43215 Dear Jim: This letter will confirm our verbal agreement that Borden, Inc. is...
Mc Merger Corp • October 15th, 1997 • Industrial inorganic chemicals

This letter will confirm our verbal agreement that Borden, Inc. is prepared to provide up to $118.5 million of funding to finance the acquisition of Melamine at a rate not to exceed 10.5% pursuant to the terms of the term loan facility under the Loan Agreement between Borden, Inc. and Borden Chemical, Inc.

Time is Money Join Law Insider Premium to draft better contracts faster.